2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

By afschroeder • August 5, 2025

Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Johnson S, Kim AY, Li JZ, MacBrayne C, Martin GS, Nadig N, Nakamura MM, Pearson JC, Riley L, Shafer RW, Shoham S, Shumaker AH, Tebas P, Tien PC, Loveless J, Morgan RL, Gandhi RT. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clin Infect Dis. 2025 Aug 4:ciaf424. doi: 10.1093/cid/ciaf424. Epub ahead of print. PMID: 40757658.

Tags: abatacept, covid-19, Harbor UCLA, Infectious Diseases, infliximab, pemivibart, Publications, vilobelimab

Association of Intracellular Microstructural and Neuropsychological Changes in HIV: A Pilot Validation of Trace Diffusion-Weighted Magnetic Resonance Spectroscopic Imaging Using Radial Trajectories

Joy A, Saucedo A, Wright MJ, Vallabhu P, Gupta N, Sayre J, Chien A, Emir U, Macey PM, Daar ES, Thomas MA. Association of Intracellular[...]

Regular Insulin Versus NPH Insulin for Continuous Enteral Tube Feeding in Hospitalized Patients

Kalangi ST, Bokka SM, Anand S, Garg R. Regular Insulin Versus NPH Insulin for Continuous Enteral Tube Feeding in Hospitalized Patients. Clin Diabetes. 2025 Apr[...]

Antiretroviral Therapy Intensification With Dolutegravir and/or Maraviroc Did Not Affect HIV-1 Cell-Associated DNA, RNA, and 2–LTR Circles Over 12 Weeks

Reed JC, Hall L, McKhann A, Kwak G, Goecker EA, Coombs RW, Chen H, Roa J, Vecchio A, Daar ES, Hunt PW, Marra CM, Campbell[...]